Highlights

  • ALS Limited reported record FY26 Revenue of $3.32 billion, up 10.7%, with underlying NPAT of $381.2 million — a 25.8% increase year-on-year.
  • Macquarie Research has issued an Outperform rating on ALQ with a price target of AUD 23.50, against the current price of AUD 23.32.
  • ALQ shares have climbed 31.68% over the past year, reflecting strong investor confidence in the commodities testing cycle and Life Sciences recovery.

ALS Limited (ASX:ALQ) is one of the world's leading testing, inspection, certification, and verification companies, operating across two primary divisions: Commodities and Life Sciences. With operations spanning more than 60 countries and a global laboratory network, ALS plays a critical role in the resources exploration Supply chain, as well as food safety, environmental testing, and pharmaceutical services.

As of 19 May 2026, ALQ shares were trading at AUD 23.32, up 1.49 or 6.83% on the day, consolidating a remarkable 31.68% gain over the past twelve months. This trajectory places ALS among the stronger performers on the ASX in the industrials and testing services space, driven by a confluence of favourable macro conditions and company-specific execution.

Broker Perspective: Macquarie's Outperform Rating

Macquarie Research has issued an Outperform rating on ALS Limited with a price target of AUD 23.50, suggesting modest near-term upside from current levels.

The Outperform designation from a major institutional research house carries weight in how fund managers and portfolio allocators assess the stock. The relatively tight gap between the current price of AUD 23.32 and the target of AUD 23.50 indicates that much of the near-term positive news may already be priced in.

FY26 Financial Results: A Record-Breaking Year

ALS delivered a standout FY26 result on 18 May 2026, reporting revenue of $3.32 billion — an increase of 10.7% on the prior year — led by robust organic growth in the Commodities division. Underlying EBIT grew 19.3% to $599 million, with the EBIT Margin expanding 129 basis points to 18.0%. This margin improvement was anchored by an exceptional 167 basis point expansion in the Commodities segment and a solid 55 basis point uplift in Life Sciences.

Underlying NPAT of $381.2 million represented a 25.8% increase, benefiting from the cyclical uptick in mineral exploration, favourable foreign exchange impacts in the first half, and reduced interest costs following the May 2025 Equity raising. Statutory NPAT came in at $318.7 million, also up 24.4%. The Minerals margin reached 33.0%, underscoring the significant Operating Leverage that ALS is generating from consistent sample Volume growth and improving pricing dynamics, particularly in the second half.

Free Cash Flow of $674.1 million was a standout metric, enabling the group to reduce leverage sharply from 2.3x to 1.5x EBITDA — well below the targeted range of 1.7x to 2.3x. EBITDA cash conversion was a healthy 92%, and group Liquidity exceeded $580 million at 31 March 2026, providing the Balance Sheet strength to pursue inorganic opportunities and fund the ongoing hub laboratory expansion program.

Divisional Deep Dive: Commodities Leading, Life Sciences Stabilising

Within the Commodities division, the Minerals Business has been the clear star performer. Exploration activity by both junior and major miners has been running at historically high levels, with junior Capital raisings particularly buoyant over the past nine months. This dynamic has fuelled sample volume growth that has stretched ALS's laboratory capacity and allowed the company to implement favourable pricing, especially for high-performance analytical methods. Industrial Materials delivered broad-based strength across Assay and Inspection, while all business units contributed to organic growth.

Life Sciences presented a more mixed picture. The Food segment continued its strong run with 7.2% organic revenue growth, driven by the compelling value proposition in European markets. However, the Environmental division encountered headwinds in the Americas during the second half — linked to the impacts of the US Government Shutdown in Q3, softer market conditions, and internal quality and cost challenges within the York business that are now under remediation. The Pharma segment, via Nuvisan, is progressing its transformation, with a two-year cost reduction programme delivering approximately €25 million in annualised savings.

Capital Allocation and Hub Laboratory Expansion

ALS invested $263 million in gross Capital Expenditure during FY26, of which approximately $230 million was growth-oriented. A major plank of the growth strategy is a $230 million hub laboratory expansion across four facilities: Lima (Peru) for Minerals Geochemistry, and Sydney (Australia), Bangkok (Thailand), and Prague (Czech Republic) for Environmental. The Lima and Sydney facilities are expected to be commissioned during the second half of FY27, adding meaningful organic capacity in strategically important geographies.

Shareholders received a final Dividend of 23.1 cents per share (30% partially franked), bringing the full-year dividend to 42.5 cents per share — a 10.1% increase on FY25 — at a Payout Ratio of approximately 57% of underlying NPAT. The dividend will be paid on 3 July 2026 to shareholders on the register at 15 June 2026.

Outlook for FY27 and the Road Ahead

Management has guided for mid-to-high single-digit organic revenue growth across the group in FY27, with margin expansion broadly similar to the FY26 improvement rate. For the Minerals segment specifically, the company anticipates 13-15% organic revenue growth for the full year, with higher confidence in 15-17% growth in the first half, consistent with the exit run rate seen in H2 FY26. Margins in Minerals are expected to be maintained at H2 FY26 levels in the first half, with a further 30-50 basis point improvement in the second half.

The Lab of the Future initiative — encompassing laboratory automation, digital infrastructure, and AI capabilities — is expected to transition from the Investment phase to early delivery in FY27, with more material returns anticipated in subsequent years. Foreign exchange is flagged as a headwind, with every 1% movement in major currencies against the AUD equating to an estimated $3 million impact on underlying EBIT. The group's procurement strategy is also designed to mitigate potential supply chain risks from the Middle Eastern conflict, with Earnings risk estimated at $5–10 million.

Conclusion

ALS Limited has delivered a record-breaking FY26 result that validates the operational leverage inherent in its global testing business model during periods of elevated exploration activity. The combination of strong free cash flow, disciplined capital allocation, a healthy balance sheet, and expanding hub laboratory capacity positions the company well for continued growth. Macquarie's Outperform rating with a $23.50 target encapsulates the view that the business remains in a favourable phase of its cycle, even as some near-term macroeconomic and FX risks Warrant monitoring. Investors tracking this stock will be watching first-half FY27 Minerals volume trends and the Environmental Americas recovery as the key swing factors for the next leg of performance.